Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment in 2025
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

Bullboard (TSXV:TLT)

View:
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 ... Next
Comment by rollthedice10on Dec 02, 2024 2:38pm

RE:RE:Small little news report from Simply Wall st.

I like this line in the analysis the best... Theralase Technologies Inc.'s (CVE:TLT) business as it appears the company may be on the cusp of a considerable accomplishment.  
43
Discussion
Comment by gordo323on Dec 02, 2024 2:07pm

RE:RE:Small little news report from Simply Wall st.

Positive L2 this AM Level II   Theralase Technologies Inc. (CA:TLT) Size Bid Ask Size 3500  ...more  
85
Discussion
Comment by McBullishon Dec 02, 2024 1:54pm

RE:Small little news report from Simply Wall st.

Same link but not on apple news https://simplywall.st/stocks/ca/healthcare/tsxv-tlt/theralase-technologies-shares/news/theralase-technologies-incs-cvetlt-path-to-profitability
69
Discussion
Post by TimboBagginson Dec 02, 2024 1:16pm

Small little news report from Simply Wall st.

doesn't say much but any publicity is good publicity  https://apple.news/A5afa9YcVTgKWxUaYxxZyQw
129
Discussion
Comment by Eoganachton Dec 02, 2024 12:40pm

RE:RE:RE:RE:Pioneering is never easy...

Hi Maxcitrac - that sounds right to me. Ruvidar PDT can treat this group of more seriously ill patients who have less chance of recovering. Despite this, 2 patients in the 103 patient CIS cohort of ...more  
139
Discussion
Comment by DeathXray33on Dec 02, 2024 11:01am

RE:RE:RE:Roger Clearly States Partner and or license deals for HSV1

Thanks Gebremeskel. I'll get them my email another way. --- I picked up some more shares today & more in a few days.
83
Discussion
Post by McBullishon Dec 02, 2024 10:30am

Any planned or submitted questions for the 12.4 call?

Perhaps we could use this thread to compile and refine a list of questions to submit to try and get a response to on the upcoming call? 
108
Discussion
Comment by Maxcitracon Dec 02, 2024 9:58am

RE:RE:RE:Pioneering is never easy...

Eoganacht, excellent summary. In your post about Adstiladrin 23.5%CR. Is it ok to say that because Adstiladrin can't treat immunodeficient patients, it does become difficult to compare Adstiladrin ...more  
155
Discussion
Comment by DeathXray33on Dec 02, 2024 8:43am

RE:Roger Clearly States Partner and or license deals for HSV1

Hi, Do you know when the newsletter comes out? I signed up for the newsletter via the Theralase website & provided my email address. Thank you.
104
Discussion
Comment by Maxcitracon Dec 02, 2024 8:41am

RE:Roger Clearly States Partner and or license deals for HSV1

Oden6570, Very good remender. R.D White: We have got a small molecule that's been tried and true and tested for various indications, so we are starting to built quite a data book on the drug, how ...more  
133
Discussion
Post by Oden6570on Dec 02, 2024 5:46am

Roger Clearly States Partner and or license deals for HSV1

Nice reminder of other developments that make your TLT shares undervalued at this time. We may see such a deal as above prior to Phase 2 Trial completion.  Theralase Technologies Announces ...more  
278
Discussion
Post by Dumbeldorfwhiteon Dec 01, 2024 10:36pm

Can’t wait to be on the call with you guys!

Who's excited to join ole Dumby on the call and how red is the sp going tomorrow?
93
Comment by Dumbeldorfwhiteon Dec 01, 2024 10:28pm

RE:RE:RE:Pioneering is never easy...

Hahahaha post of the year, yeah they ve only been trying to get BTD for 2 years now. Progressing well!
59
Discussion
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 ... Next
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT

Visit Facebook Visit X Visit Linked In Visit Instagram Visit Youtube



INVESTORS & MEDIA OVERVIEW FINANCIAL FILINGS PRESENTATIONS MEDIA FACT SHEETS MANAGEMENT

Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed in 2025, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250